November 21st, 2026Acne Treatment Adherence Ranges From 6% to 84% in Real-World StudiesReal-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.Read more
November 20th, 2026FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell TumorPimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.Read more
November 20th, 2026Real-World Brexu-cel Results in MCL Mirror Trials; Cost, QOL Data LagPooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.Read more
November 20th, 2026Health Equity & Access Weekly Roundup: November 20, 2026Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.Read more
November 20th, 2026AJMC® in the Press, November 20, 2026Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.Read more
November 19th, 2026Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty SayFaculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.Read more
November 19th, 2026FDA Approves First siRNA Therapy for AChR-Positive Myasthenia GravisThe FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.Read more
November 19th, 2026Most Patients With Psoriasis Screened Positive for PsA at One Dermatology ClinicIn a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.Read more